Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and 7-hydroxystaurosporine

gemcitabine has been researched along with 7-hydroxystaurosporine in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Azuma, A; Huang, P; Li, YX; Plunkett, W; Sampath, D; Shi, Z1
Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D1
Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC1
Beeharry, N; Caviston, JP; Rattner, JB; Yen, T1

Other Studies

5 other study(ies) available for gemcitabine and 7-hydroxystaurosporine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
    Cancer research, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Leukemia, Myeloid, Acute; S Phase; Staurosporine; Tumor Cells, Cultured

2001
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:2

    Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine

2012
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Breast cancer research : BCR, 2012, Jul-19, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2012
Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
    Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Centromere; Checkpoint Kinase 1; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Deoxycytidine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; G2 Phase Cell Cycle Checkpoints; Gemcitabine; HeLa Cells; Humans; Kinetochores; Mitosis; Protein Kinases; S Phase Cell Cycle Checkpoints; Staurosporine; Topoisomerase II Inhibitors

2013